Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ontazolast 是一种小分子白三烯B4受体(LTB4R)拮抗剂,可用于治疗免疫系统疾病和呼吸系统疾病。Ontazolast 是治疗哮喘的候选化合物。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 600 | 现货 | ||
5 mg | ¥ 1,430 | 现货 | ||
10 mg | ¥ 2,130 | 现货 | ||
25 mg | ¥ 3,620 | 现货 | ||
50 mg | ¥ 5,220 | 现货 | ||
100 mg | ¥ 7,380 | 现货 | ||
500 mg | ¥ 14,700 | 现货 |
产品描述 | Ontazolast is a small molecule leukotriene B4 receptor (LTB4R) antagonist for the treatment of immune system disorders and respiratory diseases.Ontazolast is a candidate compound for the treatment of asthma. |
体内活性 | Ontazolast is a potent inhibitor (IC50 = 1 nM) of calcium ionophore A23187-stimulated leukotriene B4 (LTB4) biosynthesis in human peripheral blood leukocytes. The emulsion formulation and three additional lipid-based formulations were administered by gavage to conscious, minimally restrained rats in a novel, double-cannulated model to determine the effects of formulation on systemic blood absorption and mesenteric lymph transport of ontazolast. The bioavailability of ontazolast was significantly and substantially enhanced by all of the lipid-based formulations. While these formulations also significantly increased the amount of ontazolast transported by the lymph, the total amounts transported were insufficient to account for the improvement in bioavailability, which may be due to the elimination or reduction of the barriers of poor aqueous solubility and slow dissolution to absorption of ontazolast from the gastrointestinal tract, or the effects of lipid on the gastrointestinal membrane permeability, transit time, or metabolism of ontazolast.[1] |
别名 | BIRM-270 |
分子量 | 335.44 |
分子式 | C21H25N3O |
CAS No. | 147432-77-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ontazolast 147432-77-7 Immunology/Inflammation LTR BIRM-270 BIRM270 BIRM 270 Inhibitor inhibitor inhibit